--(BUSINESS WIRE)--Chugai Pharmaceutical (TOKYO:4519) is one of Japan’s leading
research-based pharmaceutical companies with strengths in biotechnology
products. Chugai, based in Tokyo, specializes in prescription
pharmaceuticals and is listed on the 1st section of the Tokyo Stock
Exchange. As an important member of the Roche Group, Chugai is actively
involved in R&D activities in Japan and abroad. Specifically, Chugai is
working to develop innovative products which may satisfy the unmet
medical needs, mainly focusing on the oncology area.
In Japan,
Chugai’s research facilities in Gotemba and Kamakura are collaborating
to develop new pharmaceuticals and laboratories in Ukima are conducting
research for technology development for industrial production. Overseas,
Chugai Pharmabody Research based in Singapore is engaged in research
focusing on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai Pharma
USA and Chugai Pharma Europe are engaged in clinical development
activities in the United States and Europe.
The consolidated
revenue in 2014 of Chugai totaled 461.1 billion yen and the operating
income was 77.3 billion yen (IFRS Core basis).
|
Company: |
Chugai Pharmaceutical Co., Ltd. | |
|
Headquarters Address: |
2-1-1 Nihonbashi-Muromachi, Chuo-ku |
|
| Tokyo 103-8324 | ||
| Japan | ||
|
Main Telephone: |
81-3-3273-0881 | |
|
Website: |
||
|
Ticker: |
(TOKYO:4519) |
|
|
Type of Organization: |
Public |
|
|
Industry: |
Pharmaceutical | |
|
Key Executives: |
Chairman & CEO: Osamu Nagayama |
|
|
Deputy Chairman: Motoo Ueno |
||
|
President & COO: Tatsuro Kosaka |
||
|
Public Relations |
||
|
Contact: |
Koki Harada | |
|
Phone: |
+81-3-3273-0881 | |
|
Email: |
||
|
Investor Relations |
||
|
Contact: |
Toshiya Sasai | |
|
Phone: |
+81-3-3273-0554 |
|
|
Email: |
||
